Cardioprotection Through Mitochondrial Modulation: A Systematic Review of Pharmacological Interventions in Animal Models of I/R Injury.

Cardiovasc Drugs TherMar 4, 2026 (epub)
Clinical ResearchCardiologyOpen access

Trissha Ybanez, Joshua Ingles, Eugene Du Toit et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review assessed pharmacological interventions in animal models of myocardial ischaemia-reperfusion (I/R), focusing on cardiac outcomes, cell injury and mitochondrial bioenergetics. Eighteen papers, selected from 1571 studies, examined 15 drugs in in vivo or ex vivo models. The review found that interventions targeting electron transport chain complexes or proteins in cardioprotective pathways preserved mitochondrial respiratory capacity. This was accompanied by improved post-ischaemic cardiac function and reductions in cellular injury markers and myocardial infarction. The authors also noted unclear risk of bias in most included papers because study parameters were inadequately reported.

Key findings

  • Eighteen papers from 1571 screened studies were included, covering 15 drugs tested in animal I/R models.
  • Pharmacological interventions preserved mitochondrial respiratory capacity through direct or indirect targeting of mitochondrial pathways.
  • Preserved mitochondrial function was associated with improved post-ischaemic cardiac function and reduced cellular injury markers and myocardial infarction.
  • Most papers had unclear risk of bias because of inadequate reporting of study parameters.

Why it matters

Mitochondrial dysfunction is implicated in myocardial injury during reperfusion, and this review links pharmacological preservation of mitochondrial respiratory capacity with better cardiac outcomes in animal models. However, the unsuccessful translation of prior strategies to positive clinical trial outcomes underscores the need for cautious interpretation and better-characterised preclinical evidence before these findings can inform clinical treatment.

What to keep in mind

The evidence comes from animal models, and most included papers had unclear risk of bias because study parameters were inadequately reported.

Source

Published in Cardiovasc Drugs Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.